NOVEL THERAPEUTICS FOR AUTOIMMUNE DISEASE USING MOUSE SCREENING MODELS. The project aims to use experimental models of human autoimmune disease in the mouse for the testing of developmental isoflavonoid compounds produced by the Industry Partner, for protective effects against autoimmunity. The murine models proposed will duplicate human autoimmune cardiomyopathy, systemic lupus erythematosus and multiple sclerosis, encompassing both organ-specific and systemic autoimmune diseases. Isoflavonoi ....NOVEL THERAPEUTICS FOR AUTOIMMUNE DISEASE USING MOUSE SCREENING MODELS. The project aims to use experimental models of human autoimmune disease in the mouse for the testing of developmental isoflavonoid compounds produced by the Industry Partner, for protective effects against autoimmunity. The murine models proposed will duplicate human autoimmune cardiomyopathy, systemic lupus erythematosus and multiple sclerosis, encompassing both organ-specific and systemic autoimmune diseases. Isoflavonoid protection is anticipated from the antioxidant, anti-inflammatory and oestrogenic characteristics of these compounds/Read moreRead less
The Role of RNA interference in the induction of immune responses. Our work will allow us to understand a new means by which to alert the immune system to the presence of cancer cells using a new technology called RNA interference. This will hopefully lead to new investment in biotechnology products based on RNA interference, improved treatments for cancers and better health for Australians
The development of tyrosine kinase inhibitors for the treatment of inflammation and malignant disease. Through the combination of expertise from the Industry partner and the Hume group this project aims to develop specific inhibitors of the CSF-1 receptor protein tyrosine kinase in order to demonstrate their efficacy as modulators of CSF-1 dependent macrophage and tumour cell function in vitro. The expected outcome will be a lead set of targets which can be further assessed for therapeutic pote ....The development of tyrosine kinase inhibitors for the treatment of inflammation and malignant disease. Through the combination of expertise from the Industry partner and the Hume group this project aims to develop specific inhibitors of the CSF-1 receptor protein tyrosine kinase in order to demonstrate their efficacy as modulators of CSF-1 dependent macrophage and tumour cell function in vitro. The expected outcome will be a lead set of targets which can be further assessed for therapeutic potential in clinical trials.Read moreRead less
Comprehensive transcriptional mapping of emergent division-linked cell fate decisions. This project proposal will lead to a better understanding of the molecular mechanics that drive certain cellular behaviors. To do this, we will use a frontier technology, RNA sequencing, which we think has the potential to revolutionise Australian science and make Australia an even more attractive place for young researchers. The community at large benefits from novel technologies as they create new opportunit ....Comprehensive transcriptional mapping of emergent division-linked cell fate decisions. This project proposal will lead to a better understanding of the molecular mechanics that drive certain cellular behaviors. To do this, we will use a frontier technology, RNA sequencing, which we think has the potential to revolutionise Australian science and make Australia an even more attractive place for young researchers. The community at large benefits from novel technologies as they create new opportunities for university research and attract young minds to the challenges of maths and science.Read moreRead less
Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Austra ....Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.Read moreRead less
Antimicrobial peptides and immunological protection in a developing mammal. This project offers the opportunity to deliver both economic and scientific benefits, both in the isolation of novel antimicrobials and in positioning Australia's native fauna as important, unique biomedical research models. Antimicrobial peptides offer a solution to the current pressing problem of microbial resistance to antibiotics. This project seeks to isolate such compounds from a previously uninvestigated source, u ....Antimicrobial peptides and immunological protection in a developing mammal. This project offers the opportunity to deliver both economic and scientific benefits, both in the isolation of novel antimicrobials and in positioning Australia's native fauna as important, unique biomedical research models. Antimicrobial peptides offer a solution to the current pressing problem of microbial resistance to antibiotics. This project seeks to isolate such compounds from a previously uninvestigated source, unique to Australia. This project will provide a new perspective on the role of innate protection in a developing mammal, with possible human applications.Read moreRead less
Structure-based inhibitor design of VAP-1/SSAO for the treatment of respiratory dirsorders and other major inflammatory diseases. Inflammatory diseases, such as asthma, rheumatoid arthritis and multiple sclerosis, are widespread and often poorly treated in Australia and elsewhere. Inhibitors of the recently studied VAP-1/SSAO protein are predicted to effectively treat the inflammation symptoms of one or more of these diseases. A structure-based approach to discover these new medicines should pro ....Structure-based inhibitor design of VAP-1/SSAO for the treatment of respiratory dirsorders and other major inflammatory diseases. Inflammatory diseases, such as asthma, rheumatoid arthritis and multiple sclerosis, are widespread and often poorly treated in Australia and elsewhere. Inhibitors of the recently studied VAP-1/SSAO protein are predicted to effectively treat the inflammation symptoms of one or more of these diseases. A structure-based approach to discover these new medicines should provide a means to identify patentable compounds, with high potency, efficacy and safety. If this approach is successful, an Australian pharmaceutical company will be one of the first to the market with this new medicine to treat these chronic diseases.Read moreRead less
Investigation of Macrophage Function in an Immunologically Privileged Site. The unique phenotype of the testicular macrophage demands understanding, and this project has the potential to open up an entirely new direction of research. The basic information so generated could facilitate development of strategies to alter either host or donor tissue macrophage functions in order to prevent rejection responses in humans, and be used in the development of new anti-inflammatory drugs. Such technologie ....Investigation of Macrophage Function in an Immunologically Privileged Site. The unique phenotype of the testicular macrophage demands understanding, and this project has the potential to open up an entirely new direction of research. The basic information so generated could facilitate development of strategies to alter either host or donor tissue macrophage functions in order to prevent rejection responses in humans, and be used in the development of new anti-inflammatory drugs. Such technologies will have application in development of novel therapeutics for transplantation and the treatment of chronic inflammatory diseases. Read moreRead less
Structure and function of novel macrophage proteins using high throughput crystallography. We will combine the cutting edge technologies of microarray analysis and high throughput crystallography in an innovative approach to study the structure and function of important and uncharacterised macrophage proteins. Our strategy for targeting novel macrophage proteins will maximise the success rate of structure determination, while at the same time focusing our efforts on proteins that are important i ....Structure and function of novel macrophage proteins using high throughput crystallography. We will combine the cutting edge technologies of microarray analysis and high throughput crystallography in an innovative approach to study the structure and function of important and uncharacterised macrophage proteins. Our strategy for targeting novel macrophage proteins will maximise the success rate of structure determination, while at the same time focusing our efforts on proteins that are important in macrophage biology. Structures of the novel proteins will underpin functional analysis at a molecular level and could represent a basis for inhibitor design should the proteins ultimately be shown to be therapeutic targets.Read moreRead less
Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less